Current status and future challenges of CAR-T cell therapy for osteosarcoma
Osteosarcoma, the most common bone malignancy in children and adolescents, poses considerable challenges in terms of prognosis, especially for patients with metastatic or recurrent disease. While surgical intervention and adjuvant chemotherapy have improved survival rates, limitations such as imprac...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1290762/full |
| _version_ | 1797383008824590336 |
|---|---|
| author | Shizhe Li Shizhe Li He Zhang Guanning Shang |
| author_facet | Shizhe Li Shizhe Li He Zhang Guanning Shang |
| author_sort | Shizhe Li |
| collection | DOAJ |
| description | Osteosarcoma, the most common bone malignancy in children and adolescents, poses considerable challenges in terms of prognosis, especially for patients with metastatic or recurrent disease. While surgical intervention and adjuvant chemotherapy have improved survival rates, limitations such as impractical tumor removal or chemotherapy resistance hinder the treatment outcomes. Chimeric antigen receptor (CAR)-T cell therapy, an innovative immunotherapy approach that involves targeting tumor antigens and releasing immune factors, has shown significant advancements in the treatment of hematological malignancies. However, its application in solid tumors, including osteosarcoma, is constrained by factors such as low antigen specificity, limited persistence, and the complex tumor microenvironment. Research on osteosarcoma is ongoing, and some targets have shown promising results in pre-clinical studies. This review summarizes the current status of research on CAR-T cell therapy for osteosarcoma by compiling recent literature. It also proposes future research directions to enhance the treatment of osteosarcoma. |
| first_indexed | 2024-03-08T21:13:35Z |
| format | Article |
| id | doaj.art-a7da08a75b6f4714abef7e244088157b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T21:13:35Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a7da08a75b6f4714abef7e244088157b2023-12-22T04:25:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-12-011410.3389/fimmu.2023.12907621290762Current status and future challenges of CAR-T cell therapy for osteosarcomaShizhe Li0Shizhe Li1He Zhang2Guanning Shang3Department of Orthopaedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Orthopaedics, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, ChinaDepartment of Orthopaedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Orthopaedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, ChinaOsteosarcoma, the most common bone malignancy in children and adolescents, poses considerable challenges in terms of prognosis, especially for patients with metastatic or recurrent disease. While surgical intervention and adjuvant chemotherapy have improved survival rates, limitations such as impractical tumor removal or chemotherapy resistance hinder the treatment outcomes. Chimeric antigen receptor (CAR)-T cell therapy, an innovative immunotherapy approach that involves targeting tumor antigens and releasing immune factors, has shown significant advancements in the treatment of hematological malignancies. However, its application in solid tumors, including osteosarcoma, is constrained by factors such as low antigen specificity, limited persistence, and the complex tumor microenvironment. Research on osteosarcoma is ongoing, and some targets have shown promising results in pre-clinical studies. This review summarizes the current status of research on CAR-T cell therapy for osteosarcoma by compiling recent literature. It also proposes future research directions to enhance the treatment of osteosarcoma.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1290762/fullCAR-Tosteosarcomaimmunotherapytargeted therapytumor microenvironment |
| spellingShingle | Shizhe Li Shizhe Li He Zhang Guanning Shang Current status and future challenges of CAR-T cell therapy for osteosarcoma Frontiers in Immunology CAR-T osteosarcoma immunotherapy targeted therapy tumor microenvironment |
| title | Current status and future challenges of CAR-T cell therapy for osteosarcoma |
| title_full | Current status and future challenges of CAR-T cell therapy for osteosarcoma |
| title_fullStr | Current status and future challenges of CAR-T cell therapy for osteosarcoma |
| title_full_unstemmed | Current status and future challenges of CAR-T cell therapy for osteosarcoma |
| title_short | Current status and future challenges of CAR-T cell therapy for osteosarcoma |
| title_sort | current status and future challenges of car t cell therapy for osteosarcoma |
| topic | CAR-T osteosarcoma immunotherapy targeted therapy tumor microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1290762/full |
| work_keys_str_mv | AT shizheli currentstatusandfuturechallengesofcartcelltherapyforosteosarcoma AT shizheli currentstatusandfuturechallengesofcartcelltherapyforosteosarcoma AT hezhang currentstatusandfuturechallengesofcartcelltherapyforosteosarcoma AT guanningshang currentstatusandfuturechallengesofcartcelltherapyforosteosarcoma |